Skip to main content
OpenTrials
Completed

NCT Number: NCT00680511

Development of a Family-Based Treatment for Adolescent Methamphetamine Use

The AIMS study compares a methamphetamine-specific treatment intervention to a treatment-as-usual Functional Family Therapy (FFT) approach for adolescents ages 15 to 19. Adolescents are assigned to one of two treatment conditions: (1) 16 weeks of FFT designed to strengthen family relationships and develop skills for helping the adolescent avoid drug use; or (2) 16 weeks of a combination of FFT and a methamphetamine-specific intervention involving group and individual therapy sessions; Families are assessed using questionnaires and interviews, and adolescents participate in neuropsychological testing, before, during, and after treatment to provide information about family functioning, the adolescent's drug use, the adolescent's peers, and other factors that may contribute to treatment success. Adolescents also provide urine specimens for drug screening at assessment visits. Through a partnership with Oregon Health and Science University (OHSU), adolescents will participate in functional magnetic resonance imaging appointments at the hospital to examine regional brain blood flow during tasks designed to measure impulsivity and risk-taking behaviors. As a treatment development grant, study investigators will study adolescents' acceptance of and response to the newly developed methamphetamine-specific treatment approach.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Behavior and Mental Disorders Behavior Mental Disorders Methamphetamine Disorders

Age range

15 year–19 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Oregon Research Institute Center for Family and Adolescent Research

Portland, Oregon, 97205, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 15 to 19 years of age.
  • Have at least one parent or parent figure willing to participate.
  • Meet DSM-IV diagnostic criteria for drug-abuse or dependence, including a specific meth use disorder.
  • Reports meth use on at least 5 of the previous 90 days.
  • Have contact with the parent on at least 40% of the past 90 days.
  • With their parent be willing to accept randomization to one of the two treatment interventions.
  • Be willing to participate in the imaging task in the fMRI pilot study.
  • Have basic English competency.
  • Have sufficient residential stability to permit probable contact at follow-up.

Exclusion criteria

  • Evidence of psychotic or organic state of sufficient severity to interfere with understanding of study instruments and procedures.
  • Have a medical or psychological condition that would preclude undergoing the fMRI scan.
  • Have a sibling who is participating in the study.

Treatment and study plan

Adolescent Methamphetamine Treament (AMT)

Behavioral

AMT Group Therapy plus Functional Family Therapy (FFT)

Functional Family Therapy (FFT)

Behavioral

FFT

Primary outcomes

  1. Substance Use

    Time frame: 6 months

Secondary outcomes

  1. Engagement and retention of adolescent methamphetamine users.

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Oregon Research Institute

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Acronym: AIMS

Important dates

Study start
2007
Primary completion
2013
Study completion
2013
First posted
May 20, 2008
Registry last updated
Aug 5, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.